Attached files
| file | filename |
|---|---|
| EX-3.1 - EXHIBIT 3.1 - ARGOS THERAPEUTICS INC | exh_31.htm |
| EX-32.1 - EXHIBIT 32.1 - ARGOS THERAPEUTICS INC | exh_321.htm |
| EX-31.2 - EXHIBIT 31.2 - ARGOS THERAPEUTICS INC | exh_312.htm |
| EX-31.1 - EXHIBIT 31.1 - ARGOS THERAPEUTICS INC | exh_311.htm |
| EX-10.51 - EXHIBIT 10.51 - ARGOS THERAPEUTICS INC | exh_1051.htm |
| EX-10.50 - EXHIBIT 10.50 - ARGOS THERAPEUTICS INC | exh_1050.htm |
| EX-10.49 - EXHIBIT 10.49 - ARGOS THERAPEUTICS INC | exh_1049.htm |
| 10-K - FORM 10-K - ARGOS THERAPEUTICS INC | f10k_040218p.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Forms S-3 (Nos. 333-204016, 333-211364, 333-212645, 333-215480, 333-220001, 333-221343 and 333-222414) and Forms S-8 (Nos. 333-208055, 333-210522, 333-211403, 333-213137, 333-216985 and 333-220261) of Argos Therapeutics, Inc. of our report dated April 2, 2018 relating to the financial statements and financial statement schedule, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Raleigh, North Carolina
April 2, 2018